Canada's Aurinia Q3 revenue rises 14% on LUPKYNIS sales

Aurinia Pharmaceuticals

30/10/2026 12:12

Overview
Canada biopharma firm's Q3 total revenue rose 14% yr/yr, driven by LUPKYNIS sales
Diluted EPS for Q3 was flat yr/yr at $0.23
Company raised 2026 total revenue guidance and narrowed net product sales outlook

Outlook
Aurinia raises 2026 total revenue guidance to $325 mln-$330 mln from $315 mln-$325 mln
Company narrows 2026 net product sales guidance to $310 mln-$315 mln

Result Drivers
LUPKYNIS SALES - Co said higher sales of LUPKYNIS drove revenue growth
ROYALTY REVENUE - Increased license, collaboration and royalty revenue contributed to overall revenue growth
CLINICAL STUDY INITIATION - Co began new Phase 4 study combining LUPKYNIS with other therapies for lupus nephritis

Company press release: ID:nBw5th145a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
 
$79.42 mln
 
Q3 EPS
 
$0.23
 
Q3 Net Income
 
$31.70 mln
 
Q3 Operating Expenses
 
$48.34 mln
 
Q3 Operating Income
 
$35.36 mln
 
Q3 Pretax Profit
 
$38.72 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc. is $18.00, about 4.6% above its October 29 closing price of $17.21
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Reuters Recommended Reads
Oct 29 - Merck Q3 profit beats on Keytruda demand
Oct 28 - Biogen Q3 revenue beats on Apellis acquisition, product demand
Oct 29 - Gilead Sciences Q3 adjusted EPS beats estimates on HIV growth; raises FY2026 sales outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)